transmembrane protein 243Genealiases: C7orf23 · MM-TRAG · MMTRAG
Q-omics provides the consensus-scored TMEM243 profile across patient tissues and cancer cell-line models. TMEM243 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM243 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, TMEM243 RNA expression shows 18,797 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where TMEM243 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM243 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM243 survival associations across molecular data types. TMEM243 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM243 RNA expression–survival associations across cancer types. High TMEM243 expression shows unfavorable associations in LGG, but favorable associations in KIRC, THCA, UCS, MESO and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM243 RNA expression.
This table summarizes TMEM243 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM243. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM243 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, COAD, HNSC and KIRP. The KIRC box plot shows higher TMEM243 RNA expression in tumor versus normal tissue (log2 FC = +1.032, t-test p < 0.001).
This table shows molecular features associated with TMEM243 in patient tissues and cancer cell lines. In patient samples, TMEM243 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM243 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
